By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Deciphera Pharmaceuticals 

1505 Wakarusa Drive

Lawrence  Kansas  66047  U.S.A.
Phone: 785-838-3767 Fax: 785-838-3747



Company News
Deciphera Initiates A Phase 1 Clinical Trial Of DCC-3014 In Patients With Advanced Malignancies 3/6/2017 6:16:18 AM
Deciphera Reports Encouraging Clinical Results With DCC-2618 In Genetically-Defined Cancers With Drug Resistant Mutations 12/1/2016 8:18:26 AM
Deciphera Appoints Christopher J. Morl, M.B.A. As Chief Business Officer 10/6/2016 10:17:43 AM
Deciphera Expands Board With Appointment Of Two New Directors 10/6/2016 10:11:58 AM
Deciphera To Present At The Canaccord Genuity 36th Annual Growth Conference 8/1/2016 11:11:17 AM
Deciphera To Present At JMP Securities Life Sciences Conference 6/16/2016 11:01:23 AM
Deciphera’s Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition As A Single Agent And In Combination With An Anti-PD1 Inhibitor 4/20/2016 11:38:08 AM
Deciphera Announces Study Results For Altiratinib Demonstrating Inhibition Of Tumor Growth And Invasiveness In Glioblastoma 3/21/2016 8:34:56 AM
Deciphera To Present Data On Its Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, At AACR Annual Meeting 2016 3/17/2016 10:39:19 AM
Deciphera To Present At American Chemical Society Annual Meeting 3/9/2016 11:04:56 AM